BioSymetrics

📍 Boston, United States👥 21 employees💰 Last funded Jul 2020
Biotechnology🌐 biosymetrics.com
Website LinkedIn
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. We partner with leading healthcare and life science companies, such as Northwell Health, Janssen, Sema4, and Mt. Sinai, to increase our understanding of disease and find better drugs faster. We use a patent pending, machine learning technology called Contingent-AI™ to address bias detection and correction during pre-processing stages of machine learning and identify additional feature sets for analysis that are contingent upon decisions made during bias reduction. We combine this technology with an experimental practice that uniquely combines in silico and in vivo work to produce a faster, more precise set of predictive results for drug discovery research. We are a remote-first company with people clusters in Toronto and Boston. We are actively hiring. For more information, please visit our website at www.biosymetrics.com. #ArtificialIntelligence #AI #MachineLearning #Biotech #Healthcare #DataAnalytics #BigData #PrecisionMedicine #Pharma #LifeSciences #Genomics #DigitalHealth #DrugDiscovery #MedTech
4
Total investors
0
Early stage
4
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2019–2020 · investors recorded per year
2019320201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in BioSymetrics?
BioSymetrics has 4 investors on record on gritt.io, 4 mid-stage.
When did BioSymetrics last raise funding?
The most recent investment in BioSymetrics recorded on gritt.io was in July 2020.
What industry is BioSymetrics in?
BioSymetrics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is BioSymetrics based?
BioSymetrics is headquartered in Boston, United States.